| 词条 | Fosun Pharmaceutical |
| 释义 |
| name = Shanghai Fosun Pharmaceutical (Group) | logo = Fosun Pharma logo.png | logo_size = | logo_alt = | logo_caption = | logo_padding = | image = | image_size = | image_alt = | image_caption = | type = listed | traded_as = {{ubl|{{aligned table|{{SSE|600196}}|(A share)|{{sehk|2196}}|(H share)}}|SSE MidCap Component}} | industry = {{ubl|pharmaceutical|medical}} | founded = 1994 | founder = {{ubl|Fosun High Technology|Guangxin Technology|and 3 others}} | former_name = {{ubl|Shanghai Fortune Industrial|Shanghai Fosun Industrial}} | hq_location = | hq_location_city = Shanghai | hq_location_country = China | area_served = | num_locations = | num_locations_year = | num_employees = | num_employees_year = | key_people = {{aligned table|Chen Qiyu|(chairman)|Wu Yifang|(CEO)}} | brands = | products= | services = private hospitals | revenue = | revenue_year = | operating_income = | income_year = | net_income = {{increase}} {{CNY|link=yes|{{0}}3.125 billion}} | net_income_year = 2017 | assets = {{increase}} {{CNY|61.914 billion}} | assets_year = 2017 | equity = {{increase}} {{CNY|25.270 billion}} | equity_year = 2017 | owner = Fosun Int'l (37.94%) | parent = | subsid = {{aligned table|Sinopharm Industrial Investment|(joint venture)|Sisram Medical|(52.83%)|Gland Pharma|(74%)|Fosun Long March|(100%)|Fosun Industrial|(100%)}} | website = {{url|https://www.fosunpharma.com}} | footnotes = in consolidated financial statement[1] | module = {{Chinese|child=yes|order=st|s=上海复星医药（集团）股份有限公司|t=上海復星醫藥（集團）股份有限公司|p=Shàng hǎi fù xīng yī yào (jí tuán) gǔ fèn yǒu xiàn gōng sī|altname=Chinese short name|s2=复星医药|t2=復星醫藥|p2=fù xīng yī yào|altname3=former Chinese short name|s3=复星实业|t3=復星實業|p3=Fù xīng shí yè}} }} Shanghai Fosun Pharmaceutical (Group) Co., Ltd., known as Fosun Pharmaceutical or just Fosun Pharma is a Chinese listed pharmaceutical company. It was majority owned by Fosun International.[2] Fosun Pharmaceutical is the co-owner of Sinopharm Industrial Investment ({{zh|s=国药产业投资}}), the parent company of fellow listed company Sinopharm Group ({{zh|s=国药控股}}). The A shares of the company is a constituent of SSE 180 Index as well as its sub-index SSE MidCap Index.[3] The company was ranked 1,662nd in 2018 Forbes Global 2000, a list of top listed companies of the world.[4] HistoryFosun Pharmaceutical is a listed company which started A share[5] initial public offering in 1998 and H share in 2012.[6] The English name of the company was initially known as Shanghai Fortune Industrial Joint-Stock Co., Ltd. (SFIC; {{zh|s=上海复星实业股份有限公司}}),[7] but the transliteration of {{lang|zh|复星}} was later changed from Fortune to Fosun (as Fosun Industrial[8]), as well as changing the name from Industrial ({{zh|s=实业}}) to Pharmaceutical ({{zh|s=医药}}). The company also shorten the transliteration of the legal suffix {{lang|zh|股份有限公司}} from Joint-Stock Co., Ltd. to just Co., Ltd.. Shanghai Fortune Industrial Joint-Stock Co., Ltd. was incorporated in 1998, but its predecessor, Shanghai Fortune Industrial Company ({{zh|s=上海复星实业公司}}) was incorporated in January 1994. The majority shareholders in December 1994 were Fosun High Technology ({{zh|s=复星高科技}}) and its parent company Guangxin Technology ({{zh|s=广信科技}}); Guangxin Technology was owned by Guo Guangchang, Liang Xinjun, Wang Qunbin and Fan Wei.[5][8]{{rp|8}} In 2003 Fosun Pharmaceutical acquired 49% stake of Sinopharm Group ({{zh|s=国药控股}}).{{#tag:ref|Sinopharm Group was previously transliterated as Sinopharm Holding|group=nb}}[8]{{rp|30}}[9] In 2008, a year before the initial public offering of Sinopharm Group, Fosun Pharmaceutical owned the direct parent company of Sinopharm Group, Sinopharm Industrial Investment ({{zh|s=国药产业投资}}) instead; the majority owner of the joint venture was state-owned China National Pharmaceutical Group (Sinopharm).{{#tag:ref|China National Pharmaceutical Group itself was also transliterated as Sinopharm Group before the listing of its subsidiary, Sinopharm Group (formerly Sinopharm Holding).|group=nb}}[10][11][12] An intermediate parent company of Fosun Pharma, Fosun International (parent company of Fosun High Technology), became a listed company in 2007.[13] In 2014 Fosun Pharma was part of a consortium to acquire US-listed Chindex International, which owned private hospitals in Mainland China.[14][15] In 2016, according to the Financial Times, Fosun Pharmaceutical made the largest Indian corporate takeover by a Chinese company, by acquiring Gland Pharma for no more than US$1.26 billion.[16][17] Despite the offer was revised in 2017 to seek approval from Indian regulators.[18][19] In October 2017, the acquisition of 74% stake of Gland Pharma was completed.[1]{{rp|35–36}} In September 2017, Israeli subsidiary Sisram Medical (parent company of Alma Lasers) was spin-off as a separate listed company on the Stock Exchange of Hong Kong.[20] {{as of|2017|12|31}}, Fosun Pharma owned Sisram Medical 52.83% shares.[21] In October 2017 Fosun Pharmaceutical, via subsidiaries Fosun Pharmaceutical A.G. and Fosun Industrial{{#tag:ref|Despite it is a namesake of the former name of Fosun Pharmaceutical, Fosun Industrial ({{zh|t=復星實業（香港）有限公司|s=复星实业（香港）有限公司}}) was incorporated in Hong Kong.[1]{{rp|211}}|group=nb}} bought Tridem Pharma, according to the Financial Times, "an Africa-focused French drug distributor", for not more than €63 million.[22][23] ShareholdersFosun Pharmaceutical had two classes of ordinary share: A shares which only traded in mainland China as well as H share which only traded in Hong Kong. {{as of|2017|12|31}}, there was 2,011,190,000 number of A shares and 483,941,000 number of H shares, for a total of 2,495,131,000,[1]{{rp|174}} which Fosun International's wholly owned subsidiary, Fosun High Technology, owned 936,575,490 and 9,989,000 number of shares respectively.[1]{{rp|59}}Fosun High Technology also once owned 23.45% of the convertible bond (SSE:100196) of Fosun Pharma in 2003.[8]{{rp|6}} {{as of|2017|12|31}}, co-founder of Fosun High Technology and now co-owner of the parent company of Fosun International, Guo Guangchang and Wang Qunbin, still served as non-executive directors of Fosun Pharmaceutical.[1]{{rp|2}}{{as of|2018|7|31}}, the market capitalization of the H share of Fosun Pharma was HK$20,670,171,725.[24]Footnotes1. ^1 2 3 4 5 {{cite book|url=http://www.hkexnews.hk/listedco/listconews/SEHK/2018/0417/LTN20180417564.pdf|title=2017 Annual Report|date=17 April 2018|accessdate=5 August 2018|publisher=Fosun Pharmaceutical|via=Hong Kong Exchanges and Clearing website}} 2. ^{{cite news|url=https://www.scmp.com/business/china-business/article/2139979/fosun-pharma-chief-cites-huawei-model-overseas-expansion|title=Fosun Pharma chief cites Huawei as model for overseas expansion|last=Li|first=Jane|date=3 April 2018|work=South China Morning Post|publication-place=Hong Kong|accessdate=1 August 2018}} 3. ^{{cite web|url=http://www.csindex.com.cn/uploads/file/autofile/cons/000044cons.xls|title=SSE MidCap Constituents List|accessdate=5 August 2018|publisher=China Securities Index|type=Microsoft Excel}} 4. ^{{cite web|url=https://www.forbes.com/companies/shanghai-fosun-pharmaceutical-group/|title=Shanghai Fosun Pharmaceutical on the Forbes Global 2000 List|accessdate=6 August 2018|publisher=Forbes}} 5. ^1 {{cite book|url=http://stock.jrj.com.cn/share,disc,1998-06-23,600196,00000000000000nv4p.shtml|script-title=zh:上海复星实业股份有限公司(筹)招股说明书概要|trans-title=Prospectus of Shanghai Fortune Industrial|date=23 June 1998|accessdate=5 August 2018|publisher=Shanghai Fortune Industrial|via=jrj.com.cn|language=zh-cn}} 6. ^{{cite news|url=https://www.scmp.com/business/companies/article/1062066/fosun-pharmaceutical-begins-taking-ipo-orders-big-investors|title=Fosun Pharmaceutical begins taking IPO orders from big investors|date=16 October 2012|accessdate=5 August 2018|first=Ray|last=Chan|newspaper=South China Morning Post|publication-place=Hong Kong}} 7. ^{{cite book|url=http://static.sse.com.cn/disclosure/listedinfo/announcement/c/600196_1999_0.pdf|script-title=1999年年报|trans-title=1999 Annual Report|date=16 February 2000|accessdate=5 August 2018|publisher=Shanghai Fortune Industrial|language=zh-cn|via=Shanghai Stock Exchange website}} 8. ^1 2 3 {{cite book|url=http://static.sse.com.cn/disclosure/listedinfo/announcement/c/2004-04-24/600196_2003_n.pdf|script-title=zh:2003年年报|trans-title=2003 Annual Report|date=24 April 2004|accessdate=5 August 2018|publisher=Fosun Industrial|language=zh-cn|via=Shanghai Stock Exchange website}} 9. ^{{cite news|url=http://finance.sina.com.cn/china/20140804/112519905279.shtml|script-title=zh:国药集团复星联合成立首家混合所有制药企|date=4 August 2014|accessdate=5 August 2018|newspaper=企业观察报|language=zh-cn|via=Sina}} 10. ^{{cite book|url=http://pg.jrj.com.cn/acc/CN_DISC/STOCK_TIME/2010/03/25/101000742_nb_0000000000000310lg.pdf|script-title=zh:2009年年报|trans-title=2009 Annual Report|date=25 March 2010|accessdate=5 August 2018|publisher=Fosun Pharmaceutical|language=zh-cn|via=Shanghai Stock Exchange website}} 11. ^{{cite press release|url=http://www.hkexnews.hk/listedco/listconews/SEHK/2008/0620/LTN20080620371.pdf|title=Connection Transaction|date=20 June 2008|accessdate=6 August 2018|publisher=Fosun International |publication-place=Shanghai|via=Hong Kong Exchanges and Clearing website}} 12. ^{{cite news|url=https://hk.finance.appledaily.com/finance/daily/article/20080623/11264637|script-title=zh:復星醫藥減持國藥控股|date=23 June 2008|accessdate=6 August 2018|newspaper=Apple Daily|publication-place=Hong Kong|department="財話短說" column|publisher=Next Media|language=zh-hk}} 13. ^{{cite news|url=https://www.scmp.com/article/598383/fosun-increases-price-range-ipo-shares|title=Fosun increases price range of IPO shares|date=27 June 2007|accessdate=6 August 2018|newspaper=South China Morning Post|publication-place=Hong Kong|first=Carol|last=Chan}} 14. ^{{cite news|url=https://www.scmp.com/business/china-business/article/1494688/fosun-and-partners-buy-us-hospital-operator-chindex-us433m|title=Fosun and partners buy US hospital operator Chindex for US$433m in sweetened deal|date=23 April 2014|accessdate=5 August 2018|newspaper=South China Morning Post|publication-place=Hong Kong|agency=Bloomberg}} 15. ^{{cite news|url=https://www.ft.com/content/d23a083a-ca01-11e3-8a31-00144feabdc0|title= TPG snaps up Chinese hospital operator |date=22 April 2014|accessdate=5 August 2018|newspaper=Financial Times|publication-place=London|first=Patti|last=Waldmeir|location=Shanghai|others=Additional reporting by Zhang Yan|subscription=yes}} 16. ^{{cite news|url=https://www.ft.com/content/eb708876-54a9-11e6-9664-e0bdc13c3bef|title= Fosun to pay $1.1bn for India drugmaker Gland |date=28 July 2016|accessdate=5 August 2018|newspaper=Financial Times|publication-place=London|subscription=yes}} 17. ^{{cite press release|url=http://www.hkexnews.hk/listedco/listconews/SEHK/2016/0729/LTN20160729041.pdf|title=INSIDE INFORMATION - JOINT ANNOUNCEMENT DISCLOSEABLE TRANSACTION - ACQUISITION OF THE CONTROLLING INTEREST IN GLAND PHARMA LIMITED AND RESUMPTION OF TRADING |date=28 July 2016|accessdate=5 August 2018|publisher=Fosun International, Fosun Pharmaceutical|publication-place=Shanghai|via=Hong Kong Exchanges and Clearing website}} 18. ^{{cite news|url=https://www.ft.com/content/fafe8cf8-9bb0-11e7-8cd4-932067fbf946|title= Fosun revises its offer for India's Gland Pharma |date=18 September 2017|accessdate=5 August 2018|newspaper=Financial Times|publication-place=London|subscription=yes|location=Hong Kong|first=Don|last=Weinland}} 19. ^{{cite press release|url=http://www.hkexnews.hk/listedco/listconews/SEHK/2017/0917/LTN20170917071.pdf|title=JOINT ANNOUNCEMENT - DISCLOSEABLE TRANSACTION - PROGRESS ON ACQUISITION OF THE CONTROLLING INTEREST IN GLAND PHARMA LIMITED |date=17 September 2017|accessdate=5 August 2018|publisher=Fosun International, Fosun Pharmaceutical|publication-place=Shanghai|via=Hong Kong Exchanges and Clearing website}} 20. ^{{cite news|url=https://www.scmp.com/business/companies/article/2111622/fosun-unit-sisram-medicals-hong-kong-share-offer-draws-strong|title=Fosun unit Sisram Medical’s Hong Kong share offer draws strong investor interest, nets company US$88 million|date=18 September 2017|accessdate=5 August 2018|newspaper=South China Morning Post|publication-place=Hong Kong|first=Laura|last=He}} 21. ^{{cite book|url=http://www.hkexnews.hk/listedco/listconews/SEHK/2018/0425/LTN20180425515.pdf|title=2017 Annual Report|date=25 April 2018|accessdate=5 August 2018|publisher=Sisram Medical|via=Hong Kong Exchanges and Clearing website|chapter=Report of the Directors|pages=31–32}} 22. ^{{cite news|url=https://www.ft.com/content/dd7ca00d-6912-37f2-b8b0-0db62a5a9a6d|title= Fosun Pharmaceutical to buy French drug distributor Tridem |date=30 October 2017|accessdate=5 August 2018|newspaper=Financial Times|publication-place=London|subscription=yes}} 23. ^{{cite press release|url=http://www.hkexnews.hk/listedco/listconews/SEHK/2017/1029/LTN20171029023.pdf|title=VOLUNTARY ANNOUNCEMENT - ENTERING INTO SECURITIES PURCHASE AGREEMENT IN RELATION TO THE ACQUISITION OF THE ENTIRE EQUITY INTEREST IN TRIDEM PHARMA S.A.S|date=29 October 2017|accessdate=5 August 2018|publisher=Fosun Pharmaceutical|publication-place=Shanghai|via=Hong Kong Exchanges and Clearing website}} 24. ^{{cite web|url=http://www.hkex.com.hk/Market-Data/Statistics/Consolidated-Reports/China-Dimension?sc_lang=en&tabName=Main%20Board|title=List of H Share Companies|date=31 July 2018|accessdate=5 August 2018|publisher=Hong Kong Exchanges and Clearing Limited}} References{{reflist}}External links
10 : Pharmaceutical companies of China|Multinational companies headquartered in China|Companies based in Shanghai|Companies listed on the Hong Kong Stock Exchange|Companies listed on the Shanghai Stock Exchange|H shares|Chinese companies established in 1994|Pharmaceutical companies established in 1994|Civilian-run enterprises of China|Fosun International |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。